DiscoverExecutive Insights for Life Sciences InnovatorsCharles Swindell | CEO, Glycotest – Advancing Glycoprotein Biomarkers for Liver Disease Detection
Charles Swindell | CEO, Glycotest – Advancing Glycoprotein Biomarkers for Liver Disease Detection

Charles Swindell | CEO, Glycotest – Advancing Glycoprotein Biomarkers for Liver Disease Detection

Update: 2025-09-08
Share

Description

In this episode of Executive Insights for Life Sciences Innovators, we speak with Charles Swindell, CEO of Glycotest, about the company’s proprietary technology that measures glycoprotein fucosylation for the detection of liver diseases. Charles shares insights on the science behind Glycotest’s platform, the challenges of bringing diagnostic innovation to market, and the future of precision liver disease detection.

Learn more at genecoda.com.

Originally recorded and streamed on YouTube Live on March 14, 2025.

Comments 
loading
In Channel
00:00
00:00
1.0x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Charles Swindell | CEO, Glycotest – Advancing Glycoprotein Biomarkers for Liver Disease Detection

Charles Swindell | CEO, Glycotest – Advancing Glycoprotein Biomarkers for Liver Disease Detection

GeneCoda® Executive Search